JPS6030651B2 - 経鼻投与用インスリ製剤 - Google Patents

経鼻投与用インスリ製剤

Info

Publication number: JPS6030651B2
Authority: JP; Japan
Prior art keywords: insulin; solution; acid; surfactant; value
Prior art date: 1975-08-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP51055965A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5225013A (en

Inventor

真一郎平井

利秋池永

兌松澤

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Takeda Pharmaceutical Co Ltd

Original Assignee

Takeda Chemical Industries Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-08-20

Filing date

1976-05-14

Publication date

1985-07-17

1976-05-14 Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd

1977-02-24 Publication of JPS5225013A publication Critical patent/JPS5225013A/ja

1985-07-17 Publication of JPS6030651B2 publication Critical patent/JPS6030651B2/ja

Status Expired legal-status Critical Current

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims description 140
102000004877 Insulin Human genes 0.000 title claims description 68
108090001061 Insulin Proteins 0.000 title claims description 68
229940125396 insulin Drugs 0.000 title claims description 68
238000002360 preparation method Methods 0.000 title description 7
239000004094 surface-active agent Substances 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
229940100656 nasal solution Drugs 0.000 claims description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
239000000243 solution Substances 0.000 description 19
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
125000004432 carbon atom Chemical group C* 0.000 description 12
230000000694 effects Effects 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
229910052783 alkali metal Inorganic materials 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
150000001340 alkali metals Chemical class 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
239000008103 glucose Substances 0.000 description 7
125000001183 hydrocarbyl group Chemical group 0.000 description 7
210000002850 nasal mucosa Anatomy 0.000 description 7
-1 alkali metal salts Chemical class 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
108010005991 Pork Regular Insulin Proteins 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
150000007949 saponins Chemical class 0.000 description 4
125000004417 unsaturated alkyl group Chemical group 0.000 description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
241000700159 Rattus Species 0.000 description 3
125000003158 alcohol group Chemical group 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000002585 base Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
229930182490 saponin Natural products 0.000 description 3
235000017709 saponins Nutrition 0.000 description 3
150000005846 sugar alcohols Polymers 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 2
AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
206010040576 Shock hypoglycaemic Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000002280 amphoteric surfactant Substances 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000003833 bile salt Substances 0.000 description 2
229940093761 bile salts Drugs 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004820 blood count Methods 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000009472 formulation Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000001397 quillaja saponaria molina bark Substances 0.000 description 2
238000007391 self-medication Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 2
NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical class C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
108010007979 Glycocholic Acid Chemical class 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Chemical class C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
108010092217 Long-Acting Insulin Proteins 0.000 description 1
102000016261 Long-Acting Insulin Human genes 0.000 description 1
229940100066 Long-acting insulin Drugs 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Chemical class OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Chemical class OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
125000005037 alkyl phenyl group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960002997 dehydrocholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical class C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
229940099347 glycocholic acid Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical class C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000003595 mist Substances 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical class [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000008054 sulfonate salts Chemical class 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical class C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

JP51055965A 1975-08-20 1976-05-14 経鼻投与用インスリ製剤 Expired JPS6030651B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB34576/75		1975-08-20
GB34576/75A GB1527605A (en)	1975-08-20	1975-08-20	Insulin preparation for intranasal administration

Publications (2)

Publication Number	Publication Date
JPS5225013A JPS5225013A (en)	1977-02-24
JPS6030651B2 true JPS6030651B2 (ja)	1985-07-17

Family

ID=10367351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP51055965A Expired JPS6030651B2 (ja)	1975-08-20	1976-05-14	経鼻投与用インスリ製剤

Country Status (5)

Country	Link
JP (1)	JPS6030651B2 (fr)
BE (1)	BE841871A (fr)
DE (1)	DE2620446A1 (fr)
FR (1)	FR2321275A1 (fr)
GB (1)	GB1527605A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04126437U (ja) *	1991-05-10	1992-11-18	八木アンテナ株式会社	光受信機
EP0689052A2 (fr)	1994-06-24	1995-12-27	Toa Medical Electronics Co., Ltd.	Solution standard d'insuline

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5145405A (ja) *	1974-10-16	1976-04-17	Unyusho Kowan Gijutsu Kenkyush	Jibankairyokoho
JPS53115509A (en) *	1977-12-19	1978-10-09	Kitagawa Iron Works Co	Method of changing weak ground into stable ground
JPS53115510A (en) *	1977-12-19	1978-10-09	Kitagawa Iron Works Co	Support structure made by hardening weak soil
DE2917535C2 (de) *	1979-04-30	1986-10-30	Hoechst Ag, 6230 Frankfurt	Gegen Denaturierung beständige Insulinlösungen
EP0083619A1 (fr) *	1981-07-17	1983-07-20	Nordisk Insulinlaboratorium	Preparation therapeutique d'insuline aqueuse stable et son procede de preparation
CH657779A5 (de) *	1982-10-05	1986-09-30	Sandoz Ag	Galenische zusammensetzungen enthaltend calcitonin.
DE3371281D1 (en) *	1982-12-10	1987-06-11	Syntex Inc	Lhrh preparations for intranasal administration
IL70489A0 (en) *	1982-12-29	1984-03-30	Armour Pharma	Pharmaceutical compositions containing calcitonin
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4548922A (en) *	1983-06-06	1985-10-22	Beth Israel Hospital	Drug administration
US4746508A (en) *	1983-06-06	1988-05-24	Beth Israel Hospital Assn.	Drug administration
DE3443877A1 (de) *	1984-06-09	1985-12-12	Hoechst Ag	Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
US4658830A (en) *	1984-08-08	1987-04-21	Survival Technology, Inc.	Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
AU584184B2 (en) *	1985-04-15	1989-05-18	Eli Lilly And Company	An improved method for administering insulin
EP0200383A3 (fr) *	1985-04-15	1987-09-02	Eli Lilly And Company	Procédé pour administrer l'insuline
GB2177914B (en) *	1985-06-04	1989-10-25	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4731360A (en) *	1985-08-16	1988-03-15	Merck & Co., Inc.	Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4692441A (en) *	1985-08-16	1987-09-08	Merck & Co., Inc.	Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
DK179286D0 (da) *	1986-04-18	1986-04-18	Nordisk Gentofte	Insulinpraeparat
CA1291036C (fr) *	1986-04-23	1991-10-22	Edwin I. Stoltz	Administration de medicaments par voie nasale
NZ222907A (en) *	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) *	1986-12-16	1993-01-12	Novo Nordisk A/S	Nasal formulation and intranasal administration therewith
US5112804A (en) *	1987-04-01	1992-05-12	Temple University Of The Commonwealth System Of Higher Education	Pharmaceutical composition and method of intranasal administration
CA1335076C (fr) *	1987-04-01	1995-04-04	Hanna R. Kowarski	Composition pharmaceutique et mode d'administration par voie intranasale
US6645504B1 (en)	1987-06-24	2003-11-11	Autoimmune Inc.	Bystander suppression of type I diabetes by oral administration of glucagon
US4994439A (en) *	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
JPH0713372B2 (ja) *	1989-02-14	1995-02-15	鹿島建設株式会社	砂質土層における構造物基礎の構築方法
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5693769A (en) *	1991-12-13	1997-12-02	Transcell Technologies, Inc.	Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5795870A (en) *	1991-12-13	1998-08-18	Trustees Of Princeton University	Compositions and methods for cell transformation
US5338837A (en) *	1991-12-13	1994-08-16	The Trustees Of Princeton University	Glycosylated steroid derivatives for transport across biological membranes and process for making same
US6509006B1 (en)	1992-07-08	2003-01-21	Inhale Therapeutic Systems, Inc.	Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en)	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
CA2156717C (fr) *	1993-02-23	2001-05-29	Daniel E. Kahne	Formation en solution et dans la phase solide de liaisons glycosidiques
US5639866A (en) *	1993-02-23	1997-06-17	Princeton University	Single-step formation of multiple glycosidic linkages
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6794357B1 (en)	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
EP0748213B1 (fr)	1994-03-07	2004-04-14	Nektar Therapeutics	Procede et preparations pour l'administration d'insuline par voie pulmonaire
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
CN1088580C (zh)	1994-12-22	2002-08-07	阿斯特拉公司	气溶胶药物制剂
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5780014A (en) *	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7575761B2 (en)	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6653492B2 (en)	2001-05-02	2003-11-25	Novo Nordick A/S	Preparation of bile acids
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
DE10227232A1 (de) *	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
EP3228320B1 (fr)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Combinaison d'une insuline et d'un antagoniste glp 1
EP3202394A1 (fr)	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Préparations aqueuses de l´insuline contenant de la méthionine
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP5906194B2 (ja) *	2011-01-13	2016-04-20	株式会社カネカ	皮膚外用剤
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL62232C (fr) *		1900-01-01
US3096249A (en) *	1960-05-10	1963-07-02	Samuel J Prigal	Emulsion composition

1975
- 1975-08-20 GB GB34576/75A patent/GB1527605A/en not_active Expired
1976
- 1976-05-08 DE DE19762620446 patent/DE2620446A1/de not_active Withdrawn
- 1976-05-14 BE BE167070A patent/BE841871A/fr not_active IP Right Cessation
- 1976-05-14 JP JP51055965A patent/JPS6030651B2/ja not_active Expired
- 1976-05-14 FR FR7614707A patent/FR2321275A1/fr active Granted

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04126437U (ja) *	1991-05-10	1992-11-18	八木アンテナ株式会社	光受信機
EP0689052A2 (fr)	1994-06-24	1995-12-27	Toa Medical Electronics Co., Ltd.	Solution standard d'insuline

Also Published As

Publication number	Publication date
FR2321275B1 (fr)	1979-04-13
JPS5225013A (en)	1977-02-24
GB1527605A (en)	1978-10-04
DE2620446A1 (de)	1977-03-03
BE841871A (fr)	1976-11-16
FR2321275A1 (fr)	1977-03-18

Publication	Publication Date	Title
JPS6030651B2 (ja)	1985-07-17	経鼻投与用インスリ製剤
US4153689A (en)	1979-05-08	Stable insulin preparation for nasal administration
DE3880346T2 (de)	1993-07-29	Insulinderivate.
US4548922A (en)	1985-10-22	Drug administration
EP0147526B1 (fr)	1988-12-28	Méthode pour l'augmentation de la résorption entérique de l'héparine et préparations contenant de l'héparine ainsi obtenues
DE2620483A1 (de)	1976-12-23	Stabile waessrige insulinloesungen
CS273139B1 (en)	1991-03-12	Method of pharmaceutical agent production for intranasal feed
DE19627392A1 (de)	1997-01-16	Medikament zur Verabreichung durch die Nase
EP0145209B1 (fr)	1989-10-11	Kit ou dispositif et méthode pour administrer des gangliosides et leurs dérivés par inhalation et compositions pharmaceutiques appropriées
JPS61218510A (ja)	1986-09-29	毛髪用剤
US4789660A (en)	1988-12-06	Insulin administration using methyl and propyl paraben
AT396475B (de)	1993-09-27	Säureadditionssalze aus amidiertem taurin oder glycin, deren herstellung und verwendung
JPH0228121A (ja)	1990-01-30	経粘膜吸収促進剤及びこれを用いた経鼻投与剤
US6008189A (en)	1999-12-28	Intravaginal preparation containing physiologically active peptide
NL8203314A (nl)	1983-03-16	Farmaceutische preparaten, die menselijk insuline en menselijk pro-insuline bevatten.
US3914416A (en)	1975-10-21	Certain monomethyl trisilanol mannuronate complexes for treating cellulitis
DE3601923A1 (de)	1987-07-30	Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung
DE3881254T2 (de)	1993-09-02	Pharmazeutische zusammensetzung.
US4389414A (en)	1983-06-21	Prostaglandin compositions
EP0324745B1 (fr)	1995-01-11	Agents topiques contenant des derives de prostacycline
JPS62207226A (ja)	1987-09-11	経鼻投与用製剤
NL8203316A (nl)	1983-03-16	Farmaceutische preparaten met menselijk pro-insuline.
JP3534793B2 (ja)	2004-06-07	グリチルリチン酸直腸製剤
CN1239436A (zh)	1999-12-22	用于将肽药物引入生物体的局部制剂
JPH01308235A (ja)	1989-12-12	ヒト成長ホルモン経鼻剤

JPS6030651B2 - 経鼻投与用インスリ製剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=10367351

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (68)

Family Cites Families (2)

Cited By (2)

Also Published As

Similar Documents